{"id":205427,"date":"2026-08-17T09:39:43","date_gmt":"2026-08-17T04:09:43","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=205427"},"modified":"2026-08-17T09:39:44","modified_gmt":"2026-08-17T04:09:44","slug":"sun-pharma-share-price-lipitor-antitrust-us-court-august-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sun-pharma-share-price-lipitor-antitrust-us-court-august-2026\/","title":{"rendered":"Sun Pharma Share Price in Focus After US Court of Appeals Affirms Summary Judgment in Sun Pharma’s Favour in Lipitor Antitrust Litigation on 17 August 2026"},"content":{"rendered":"
<\/div>\n

Sun Pharma share price: US Court of Appeals (Third Circuit) affirmed District Court summary judgment in Sun Pharma’s favour in Lipitor (Atorvastatin) antitrust litigation. Court also affirmed denia…<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The Sun Pharma share price is in focus on 17 August 2026 after the United States Court of Appeals for the Third Circuit affirmed the District Court’s summary judgment in Sun Pharmaceutical Industries’ favour in the long-running Lipitor antitrust litigation. The court also affirmed orders denying class certification in the case.<\/p>\n<\/div>\n

The Sun Pharma share price has a major legal positive to factor in on 17 August 2026. The United States Court of Appeals for the Third Circuit has affirmed the District Court’s summary judgment entirely in Sun Pharmaceutical Industries’ favour in the Lipitor antitrust litigation. The Third Circuit also affirmed the District Court’s orders denying class certification against the plaintiffs. This dual affirmation \u2014 on the merits and on class certification \u2014 represents a comprehensive legal victory that removes a significant litigation overhang from the Sun Pharma share price.<\/p>\n

The Lipitor (Atorvastatin) antitrust litigation has been a long-running legal matter for Sun Pharma since it originates from a 2008 patent settlement with Pfizer. Plaintiffs alleged the settlement unlawfully delayed generic competition for the blockbuster cholesterol drug Lipitor, which had been one of the world’s best-selling pharmaceuticals. Sun Pharma and its subsidiaries have been among the defendants in this complex multi-party antitrust action. The Third Circuit’s affirmation of the summary judgment means the antitrust claims against Sun Pharma did not have sufficient legal merit to proceed to trial.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n